600704:SSEWuchan Zhongda Group Co., Ltd. Class A Analysis
Data as of 2026-03-12 - not real-time
CN¥5.63
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Wuchan Zhongda Group trades at CNY 5.63, hovering just below its 20‑day SMA (5.66) and 50‑day SMA (5.72), indicating a lack of upward momentum. The 14‑day RSI sits at 47.4, comfortably away from overbought levels, while the MACD histogram remains negative, signaling short‑term bearish pressure. Volume has been increasing, but 30‑day price volatility is high at ~24.9%, suggesting price swings could continue. The stock’s beta of 0.05 points to minimal market‑wide correlation, yet the recent max drawdown of 15.6% highlights downside risk. Fundamentally, revenue fell 2.3% year‑over‑year and margins are razor‑thin (gross 2.0%, operating 1.5%, profit 0.64%). Despite these challenges, the company offers a generous dividend yield of 5.55% with a payout ratio of 29%.
Valuation metrics are compelling: a trailing P/E of 7.8 is far below the industry average of 29.6, and the price‑to‑book of 0.71 suggests a discount to net assets. However, cash generation is weak—operating cash flow and free cash flow are both negative—and debt‑to‑equity stands at 87.7%, raising concerns about dividend sustainability. The forward P/E of 6.5 hints at modest earnings improvement, supporting a medium‑term upside case. Given the mix of attractive yield, deep valuation discount, and elevated financial risk, the stock appears undervalued from a value perspective but carries notable execution risk. Investors should weigh the high dividend against the company’s cash‑flow strain and leverage before taking a position. Overall, the setup favors a cautious approach with a bias toward buying on dips while monitoring liquidity and debt metrics.
Valuation metrics are compelling: a trailing P/E of 7.8 is far below the industry average of 29.6, and the price‑to‑book of 0.71 suggests a discount to net assets. However, cash generation is weak—operating cash flow and free cash flow are both negative—and debt‑to‑equity stands at 87.7%, raising concerns about dividend sustainability. The forward P/E of 6.5 hints at modest earnings improvement, supporting a medium‑term upside case. Given the mix of attractive yield, deep valuation discount, and elevated financial risk, the stock appears undervalued from a value perspective but carries notable execution risk. Investors should weigh the high dividend against the company’s cash‑flow strain and leverage before taking a position. Overall, the setup favors a cautious approach with a bias toward buying on dips while monitoring liquidity and debt metrics.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish MACD histogram
- Price below 20‑day SMA
- High short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Low P/E vs industry
- High dividend yield
- Forward earnings growth
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative operating cash flow
- Elevated debt‑to‑equity
- Thin profit margins
Key Metrics & Analysis
Financial Health
Revenue Growth-2.30%
Profit Margin0.64%
P/E Ratio7.8
ROE10.25%
ROA0.91%
Debt/Equity87.70
P/B Ratio0.7
Op. Cash FlowCN¥-2585170944
Free Cash FlowCN¥-3639840256
Industry P/E29.6
Technical Analysis
TrendNeutral
RSI47.4
SupportCN¥5.46
ResistanceCN¥5.87
MA 20CN¥5.66
MA 50CN¥5.72
MA 200CN¥5.64
MACDBearish
VolumeIncreasing
Fear & Greed Index75.32
Valuation
GradeUndervalued
TypeValue
Dividend Yield5.55%
Risk Assessment
Beta0.05
Volatility24.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.